Reporting adverse drug events to the Therapeutic Goods Administration

Jennifer H Martin^{1

2}, Catherine Lucas^{1

2}

Affiliations

¹ Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, New South Wales.
² Hunter New England Health, Newcastle, New South Wales.

Editorial

Jennifer H Martin et al. Aust Prescr. 2021 Feb.

. 2021 Feb;44(1):2-3.

doi: 10.18773/austprescr.2020.077. Epub 2021 Feb 1.

Jennifer H Martin^{1

2}, Catherine Lucas^{1

2}

¹ Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, New South Wales.
² Hunter New England Health, Newcastle, New South Wales.

No abstract available

Keywords: Therapeutic Goods Administration; adverse drug reaction reporting systems; drug-related side effects and adverse reactions.

Conflict of interest statement

Conflict of interest: none declared

1. Linger M, Martin J. Pharmacovigilance and expedited drug approvals. Aust Prescr 2018;41:50-3. 10.18773/austprescr.2018.010 - DOI - PMC - PubMed
1. Therapeutic Goods Administration. Half yearly performance snapshot: July to December 2019. Canberra: Commonwealth of Australia; 2020. https://www.tga.gov.au/publication/half-yearly-performance-snapshot-july... [cited 2021 Jan 4]
1. Mackay K. Showing the blue card: reporting adverse reactions. Aust Prescr 2005;28:140-2. 10.18773/austprescr.2005.107 - DOI
1. Wiktorowicz ME, Lexchin J, Paterson M, Mintzes B, Metge C, Light D, et al. Research networks involved in post-market pharmacosurveillance in the United States, United Kingdom, France, New Zealand, Australia, Norway and European Union: lessons for Canada. Edmonton (AB): Canadian Patient Safety Institute; 2008. https://www.patientsafetyinstitute.ca/en/toolsResources/ Research/commis... researchResults.aspx [cited 2021 Jan 4]
1. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf 2006;29:385-96. 10.2165/00002018-200629050-00003 - DOI - PubMed